Marshall Wace, LLP Idera Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.53 - $1.03 $215,830 - $419,443	-407,227 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$1.0 - $1.18 $70,222 - $82,861	-70,222 Reduced 14.71%	407,227 $419,000
Q2 2021 Aug 13, 2021	BUY	$1.01 - $1.58 $482,223 - $754,369	477,449 New	477,449 $573,000
Q1 2021 May 17, 2021	SELL	$1.23 - $5.98 $12,402 - $60,296	-10,083 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$2.09 - $5.18 $21,073 - $52,229	10,083 New	10,083 $37,000
Q1 2019 May 14, 2019	SELL	$2.33 - $3.79 $94,700 - $154,040	-40,644 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$2.77 - $9.38 $50,261 - $170,200	18,145 Added 80.65%	40,644 $113,000
Q3 2018 Nov 14, 2018	BUY	$5.53 - $11.36 $124,419 - $255,588	22,499 New	22,499 $200,000

Ticker IDRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,296,900
Market Cap $188M
Description
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating s...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.